Benchmark Starts Vascular Solutions (VASC) at Buy; Catheter Products are Key
Tweet Send to a FriendGet Alerts VASC Hot Sheet
Price: $15.79 -4.59%
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VASC Now!
Benchmark initiates coverage on Vascular Solutions (NASDAQ: VASC) with a Buy. PT $15.00.
Analyst, James Terwilliger, said, "In Q1:12, VASC posted Catheter products revenue of $14.9 million. This represented 18% growth compared to the same period last year and represented 63% of total revenue for the quarter. We are encouraged by the strong growth that was visible in Q1:12 as the Pronto aspiration catheter product line faced competitive price pressure. Even with this pressure, the division generated 18% growth and we estimate that if we exclude the Pronto business, which is under pressure, then growth in the Catheter products division would have been in a range of 20-25%...For 2012, we estimate Catheter product revenue of $61.9 million or 63% of total revenue. This represents a 17% growth rate compared to the same period last year. For 2013, we estimate Catheter revenue of $70.5 million."
For an analyst ratings summary and ratings history on Vascular Solutions click here. For more ratings news on Vascular Solutions click here.
Shares of Vascular Solutions closed at $11.87 yesterday, with a 52 week range of $9.90-$13.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, James Terwilliger, said, "In Q1:12, VASC posted Catheter products revenue of $14.9 million. This represented 18% growth compared to the same period last year and represented 63% of total revenue for the quarter. We are encouraged by the strong growth that was visible in Q1:12 as the Pronto aspiration catheter product line faced competitive price pressure. Even with this pressure, the division generated 18% growth and we estimate that if we exclude the Pronto business, which is under pressure, then growth in the Catheter products division would have been in a range of 20-25%...For 2012, we estimate Catheter product revenue of $61.9 million or 63% of total revenue. This represents a 17% growth rate compared to the same period last year. For 2013, we estimate Catheter revenue of $70.5 million."
For an analyst ratings summary and ratings history on Vascular Solutions click here. For more ratings news on Vascular Solutions click here.
Shares of Vascular Solutions closed at $11.87 yesterday, with a 52 week range of $9.90-$13.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Vascular Solutions Files Patent Infringement Complaint Against Boston Scientific
- Credit Suisse Starts New Residential Investment (NRZ) at Outperform
- BTIG Starts Ambac Financial (AMBC) at Buy, Interesting Play with 'Optionality'
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
